December 27, 2010: Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar.
December 21, 2011: Vicus Therapeutics to Present at Biotech Showcase, Wednesday, January 12, 2011 at 2:45pm PST.
Oct 2, 2011: Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents. This is more content.
July 1, 2011: Beta blocker associated with improved relapse free survival in triple negative breast cancer.